welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Sedation During Muscle Biopsy in Patients With Duchenne Muscular Dystrophy
study id #: NCT01645098
condition: Duchenne Muscular Dystrophy
This is an interventional study on Duchenne muscular dystrophy patients who will be receiving sedation for a muscle biopsy as part of another study.
intervention: Ketamine, Dexmedetomidine
mechanism of action: Sedation during moderately painful procedures
last updated: November 22, 2018
start date: August 2011
estimated completion: June 2013
phase of development: N/A
size / enrollment: 53
- Time to Sedation Score of 3-4 [ Time Frame: Immediately prior to incision ]
The depth of sedation was judged using the University of Michigan Sedation Scale (UMSS). The score ranges from zero, awake and alert, to four, unarousable. A score of three, deeply sedated, or more was considered to be an appropriate level of sedation for the procedure.
- Heart Rate Change After Dexmedetomidine Loading Dose [ Time Frame: Baseline to immediately post dexmedetomidine infusion. ]
Difference in heart rate from baseline to immediately following infusion of dexmedetomidine loading dose.
- Mean Arterial Pressure (MAP) Change After Dexmedetomidine Loading Dose [ Time Frame: Baseline to immediately post dexmedetomidine infusion. ]
Change in MAP from baseline measurement to immediately post dexmedetomidine infusion measured via blood pressure cuff.
- Oxygen Saturation Change After Dexmedetomidine Loading Dose [ Time Frame: Baseline to immediately post dexmedetomidine infusion. ]
Change in oxygen saturation from baseline measurement to immediately post dexmedetomidine infusion.
- EtCO2 Change After Dexmedetomidine Loading Dose [ Time Frame: Baseline to immediately post dexmedetomidine infusion. ]
Change in end-tidal carbon dioxide from baseline measurement to immediately post dexmedetomidine infusion.
Patients undergoing a muscle biopsy for IRB11-00203.
MoveDMD: phase 2 trial of edasalonexent, an NF-κB inhibitor, in 4 to 7-year old patients with Duchenne muscular dys...NF-κB is activated from infancy in DMD,...
Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Duchenne Muscular Dystroph...The proposed clinical trial is an outgro...
Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular DystrophyThe objective is to determine whether ne...
Molecular Analysis of Patients With Neuromuscular DiseaseThe purpose of this study is to identify...
Givinostat in Duchenne’s Muscular Dystrophy Long-term Safety and Tolerability StudyThis is an open label, long-term safety,...
Study of Ataluren in >=2 to <5 Year-Old Males With Duchenne Muscular DystrophyThis is a Phase 2, multiple-dose, open-l...
A Study of TAS-205 for Duchenne Muscular DystrophyThe objective of this study is to evalua...
Clinical trial shows some promise for Duchenne muscular dystrophy drugThe results of an international clinical...
Solid Biosciences Reports Third Quarter 2018 Financial Results And Provides Business UpdateSolid Biosciences Inc. today reported fi...
First Patient Dosed in Phase II Clinical Trial in Duchenne Muscular DystrophyAntisense Therapeutics today announced d...
ReveraGen Announces First Patient Enrollment in International Pivotal Trial of Vamorolone in Duchenne Muscular Dystr...ReveraGen BioPharma, Inc. today announce...